Fulltext

Influence of Hepatitis C Virus Infection on HIV-1 Disease Progression and Response to Highly Active Antiretroviral Therapy

Rockstroh, Jürgen K. ; Mocroft, Amanda ; Soriano, Vincent ; Tural, Cristina ; Losso, Marcello H. ; Horban, Andrzej ; Kirk, Ole ; Phillips, Andrew ; Ledergerber, Bruno ; Lundgren, Jens

In: The Journal of Infectious Diseases, 2005, vol. 192, no. 6, p. 992-1002

Add to personal list
    Title
    • Influence of Hepatitis C Virus Infection on HIV-1 Disease Progression and Response to Highly Active Antiretroviral Therapy
    Author
    • Rockstroh, Jürgen K.. Department of Medicine I, University Hospital Bonn, Bonn, Germany
    • Mocroft, Amanda. Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, United Kingdom
    • Soriano, Vincent. Service of Infectious Diseases and Hepatology Unit, Hospital Carlos III, Madrid, and
    • Tural, Cristina. HIV Clinical Unit and IrsiCaixa Retrovirology Laboratory, Hospital Universitari Germans Trias Pujol, Universitat Autónoma de Barcelona, Badalona, Spain
    • Losso, Marcello H.. Hospital Jose Maria Ramos Mejía, Buenos Aires, Argentina
    • Horban, Andrzej. Centrum Diagnostyki i Terapii AIDS, Warsaw, Poland
    • Kirk, Ole. EuroSIDA Coordinating Centre, Copenhagen HIV-Programme, Hvidovre University Hospital, Copenhagen, Denmark
    • Phillips, Andrew. Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, United Kingdom
    • Ledergerber, Bruno. University Hospital, Zurich, Switzerland
    • Lundgren, Jens. EuroSIDA Coordinating Centre, Copenhagen HIV-Programme, Hvidovre University Hospital, Copenhagen, Denmark
    Document Type
    • Postprint
    Language
    • English
    Published in
    • The Journal of Infectious Diseases, 2005, vol. 192, no. 6, p. 992-1002. The University of Chicago Press
    Other Version
    Classification
    • Health
    OAI-PMH Identifier
    • oai:doc.rero.ch:302416
    Summary
    ObjectiveTo assess hepatitis C virus (HCV) antibody prevalence in the EuroSIDA cohort, along with survival, human immunodeficiency virus (HIV)-1 disease progression, virologic response (plasma HIV-1 RNA load of <500 copies/mL), and CD4 cell count recovery by HCV serostatus in patients initiating highly active antiretroviral therapy (HAART) ResultsHCV serostatus at or before enrollment was available for 5957 patients; 1960 (33%) and 3997 (67%) were HCV seropositive and seronegative, respectively. No association between an increased incidence of acquired immunodeficiency syndrome-defining illnesses or death and HCV serostatus was seen after adjustment for other prognostic risk factors known at baseline (adjusted incidence rate ratio [IRR], 0.97 [95% confidence interval {CI}, 0.81-1.16]). However, there was a large increase in the incidence of liver disease-related deaths in HCV-seropositive patients in adjusted models (IRR, 11.71 [95% CI, 6.42-21.34]). Among 2260 patients of known HCV serostatus initiating HAART, after adjustment, there was no significant difference between HCV-seropositive and -seronegative patients with respect to virologic response (relative hazard [RH], 1.13 [95% CI, 0.84-1.51]) and immunologic response, whether measured as a ⩾50% increase (RH, 0.94 [95% CI, 0.77-1.16]) or a ⩾50 cells/μL increase (RH, 0.92 [95% CI, 0.77-1.11]) in CD4 cell count after HAART initiation ConclusionsHCV serostatus did not affect the risk of HIV-1 disease progression, but the risk of liver disease-related deaths was markedly increased in HCV-seropositive patients. The overall virologic and immunologic responses to HAART were not affected by HCV serostatus